HTR5A and metabolic dysfunction-associated steatotic liver disease: Evidence in rats suggests that gut-derived 5-HT contributes to the progression of NASH via the 5-HT2A/PPARγ2 pathway in the liver, where e.g. 5-HT receptor antagonists reduced NAFLD progression12, while its effect in human liver is still unknown.